Immune Design Announces Dosing Of Patients In Phase 1b Trial Of CMB305

(RTTNews) - Immune Design (IMDZ) announced the dosing of patients in a Phase 1b clinical trial of CMB305, an immuno-oncology product candidate generated from the company's ZVexTM and GLAASTM platforms. The Phase 1b open label, multi-center trial is designed to evaluate the safety and tolerability, immunogenicity, and preliminary clinical efficacy of CMB305 in patients with locally advanced, relapsed or metastatic solid cancers expressing NY-ESO-1, a tumor antigen found in a broad set of tumors.

CMB305 is a combination product that involves the sequential dosing of two complementary agents, LV305 and G305, and is designed to synergistically induce anti-tumor cytotoxic T lymphocytes to target tumors that express NY-ESO-1.